Q2 EPS Estimate for Denali Therapeutics Raised by Analyst

Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) - Equities research analysts at Wedbush increased their Q2 2025 earnings per share (EPS) estimates for shares of Denali Therapeutics in a report issued on Wednesday, May 7th. Wedbush analyst L. Chico now anticipates that the company will earn ($0.76) per share for the quarter, up from their previous forecast of ($0.77). Wedbush currently has a "Outperform" rating and a $30.00 price target on the stock. The consensus estimate for Denali Therapeutics' current full-year earnings is ($2.71) per share. Wedbush also issued estimates for Denali Therapeutics' FY2025 earnings at ($3.17) EPS, Q4 2026 earnings at ($0.78) EPS, FY2026 earnings at ($3.16) EPS, FY2027 earnings at ($2.77) EPS and FY2028 earnings at ($1.10) EPS.

Several other equities analysts also recently commented on the company. Bank of America dropped their target price on Denali Therapeutics from $30.00 to $28.00 and set a "buy" rating for the company in a research report on Monday, March 10th. Morgan Stanley initiated coverage on Denali Therapeutics in a research note on Friday, March 7th. They set an "overweight" rating and a $33.00 target price for the company. HC Wainwright reduced their price objective on Denali Therapeutics from $80.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. William Blair raised Denali Therapeutics to a "strong-buy" rating in a research note on Thursday, April 24th. Finally, Cantor Fitzgerald raised Denali Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Thursday, April 10th. One analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $33.79.

Denali Therapeutics Price Performance

Shares of DNLI stock traded down $0.19 on Monday, hitting $13.97. 134,021 shares of the company's stock were exchanged, compared to its average volume of 1,091,593. The stock has a market cap of $2.03 billion, a P/E ratio of -5.05 and a beta of 1.49. Denali Therapeutics has a 12 month low of $10.57 and a 12 month high of $33.33. The company has a 50 day moving average of $14.13 and a 200 day moving average of $19.74.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported ($0.78) earnings per share for the quarter, missing the consensus estimate of ($0.71) by ($0.07). During the same period last year, the company posted ($0.68) earnings per share.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. KLP Kapitalforvaltning AS purchased a new position in shares of Denali Therapeutics during the 4th quarter valued at $532,000. Proficio Capital Partners LLC purchased a new position in shares of Denali Therapeutics during the 4th quarter valued at $514,000. JPMorgan Chase & Co. lifted its position in shares of Denali Therapeutics by 6.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 235,386 shares of the company's stock valued at $6,857,000 after buying an additional 14,324 shares during the last quarter. Principal Financial Group Inc. lifted its position in shares of Denali Therapeutics by 13.8% during the 3rd quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company's stock valued at $36,076,000 after buying an additional 149,939 shares during the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Denali Therapeutics by 7.6% during the 4th quarter. Vanguard Group Inc. now owns 12,021,230 shares of the company's stock valued at $244,993,000 after buying an additional 843,996 shares during the last quarter. Hedge funds and other institutional investors own 92.92% of the company's stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.